Previous 10 | Next 10 |
Arbutus Biopharma ( NASDAQ: ABUS ) on Wednesday said its phase 2a hepatitis B virus infection trial with partner Assembly Biosciences ( ASMB ) evaluating a combination involving drug candidates by both companies would continue, despite ASMB's decision to stop deve...
Shares of Assembly Biosciences ( NASDAQ: ASMB ) fell 7.4% after hours as the company said it would discontinue the development of its inhibitor vebicorvir for the treatment of hepatitis B virus and would reduce its workforce by about 30%. As a result of the discontinua...
- Discontinues clinical development of vebicorvir, Assembly Bio’s first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies - Advancing next-generation, significantly more potent core inhibitors, ABI-H3733 and ABI-4334, in cli...
Two triple-combination studies using AB-729 for treatment of patients with Hepatitis B are expected in the 2nd half of 2022. A PD-L1 drug is being advanced in the pipeline to eventually add to a triple combination regimen with AB-729; In addition, potential to advance very same drug f...
SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced data from the...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The definition varies with countries but in the U.S., a penny stock is one which is trading under $5 and is often referred to as a micro-cap. A micro-cap is a company whose market capitalization is between $50 million and $...
Assembly Bio leadership team will be joined by Professor Edward J. Gane, MBCHB, MD, FRACP, MNZM, an internationally-recognized hepatologist, and authority and investigator in hepatitis clinical trials SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Assem...
SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that six abstracts...
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced the initiation of ...
Assembly Biosciences press release (NASDAQ:ASMB): Q1 GAAP EPS of -$0.48. Cash and cash equivalents of $51.17M For further details see: Assembly Biosciences GAAP EPS of -$0.48
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...